

Addressing the Global Burden of Atopic Dermatitis:

Navigating Evolving Best Practices for Diagnosis and Treatment

SELECTED READINGS

General/Global

Bailiff OA, Mowad CM. Mimics of Dermatitis. *Immunol Allergy Clin North Am*. 2021;41(3):493-515.

Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. *Am J Clin Dermatol*. 2022;23(3):393-408.

Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. *Allergy*. 2020;75(1):54-62.

Brunner PM, Guttman-Yassky E. Racial differences in atopic dermatitis. *Ann Allergy Asthma Immunol*. 2019;122(5):449-455.

Eichenfield LF, Stripling S, Fung S, Cha A, O'Brien A, Schachner LA. Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting. *Paediatr Drugs*. 2022;24(4):293-305.

Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. *J Am Acad Dermatol*. 2021;84(1):139-147.

Halling AS, Thyssen JP. Biological therapy for young children with atopic dermatitis. *Lancet*. 2022;400(10356):867-869.

Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. *Allergy Asthma Proc*. 2019;40(2):84-92.

Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. *Exp Dermatol*. 2018;27(4):340-357.

Langan SM, Irvine AD, Weidinger S. Atopic dermatitis [published correction appears in *Lancet*. 2020 Sep 12;396(10253):758]. *Lancet*. 2020;396(10247):345-360.

Mosam A, Todd G. Global epidemiology and disparities in atopic dermatitis [published online ahead of print, 2023 Mar 7]. *Br J Dermatol*. 2023;ljad042.

Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2022;400(10356):908-919.

Tsiogka A, Kyriazopoulou M, Kontochristopoulos G, et al. The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review. *J Clin Med*. 2022;11(15):4431.

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. *Nat Rev Dis Primers*. 2018;4(1):1.

Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. *J Am Acad Dermatol*. 2019;80(2):390-401.

Wu JJ, Martin A, Liu J, et al. The risk of COVID-19 infection in patients with atopic dermatitis: A retrospective cohort study. *J Am Acad Dermatol*. 2022;86(1):243-245.

Africa/Middle East

Al-Afif KAM, Buraik MA, Buddenkotte J, et al. Understanding the Burden of Atopic Dermatitis in Africa and the Middle East. *Dermatol Ther (Heidelb)*. 2019;9(2):223-241.

Faye O, Meledie N'Djong AP, Diadie S, et al. Validation of the Patient-Oriented SCORing for Atopic Dermatitis tool for black skin. *J Eur Acad Dermatol Venereol*. 2020;34(4):795-799.

Mouna K, Ben Hamouda M, Hichem B, Lahouel M, Monia Y, Jameleddine Z. Evaluation of a Modified Version of the United Kingdom Working Party Diagnostic Criteria for Atopic Dermatitis in Tunisia. *Dermatitis*. 2022;33(6S):S119-S123.

Schmid-Grendelmeier P, Takaoka R, Ahogo KC, et al. Position Statement on Atopic Dermatitis in Sub-Saharan Africa: current status and roadmap. *J Eur Acad Dermatol Venereol*. 2019;33(11):2019-2028.

Skevaki C, Ngocho JS, Amour C, Schmid-Grendelmeier P, Mmbaga BT, Renz H. Epidemiology and management of asthma and atopic dermatitis in Sub-Saharan Africa. *J Allergy Clin Immunol*. 2021;148(6):1378-1386.

Asia/Asia-Pacific

Katoh N, Saeki H, Kataoka Y, et al. Evaluation of standard treatments for managing adult Japanese patients with inadequately controlled moderate-to-severe atopic dermatitis: Two-year data from the ADDRESS-J disease registry. *J Dermatol*. 2022;49(9):903-911.

Lee EM, Cho YT, Chan TC, Shen D, Chu CY, Tang CH. Economic Burden of Atopic Dermatitis in Taiwan. *Acta Derm Venereol*. 2023;103:adv00866.

Noda S, Suárez-Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. *J Allergy Clin Immunol*. 2015;136(5):1254-1264.

Sarkar R, Narang I. Childhood atopic dermatitis-An Indian perspective. *Pediatr Dermatol*. 2018;35(5):e330-e331.

Tanaka A, Niimi N, Takahashi M, et al. Prevalence of skin diseases and prognosis of atopic dermatitis in primary school children in populated areas of Japan from 2010 to 2019: The Asa Study in Hiroshima, Japan. *J Dermatol*. 2022;49(12):1284-1290.

Zhao Y, Wu L, Lu Q, et al. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. *Br J Dermatol*. 2022;186(4):633-641.

Latin America

Borzutzky A, Larco JI, Luna PC, et al. Atopic Dermatitis in Latin America: A Roadmap to Address Data Collection, Knowledge Gaps, and Challenges. *Dermatitis*. 2022;33(6S):S83-S91.

Maspero JF, Cardona G, Schonffeldt P, et al. Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study. *J Asthma*. 2023;60(5):981-990.

Sánchez J, Sánchez A, Cardona R. Critical review of ISAAC results for atopic dermatitis in tropical cities. Revisión crítica de los resultados del ISAAC para dermatitis atópica en ciudades del trópico. *Rev Alerg Mex*. 2018;65(4):389-399.

Sánchez J, Sánchez A, Cardona R. Particular characteristics of atopic eczema in tropical environments. The Tropical Environment Control for Chronic Eczema and Molecular Assessment (TECCEMA) cohort study. *An Bras Dermatol*. 2017;92(2):177-183.